HSP90AA1 and neoplasm: Since tumor cells expressing high levels of BRCA1 are resistant to both IR and several classes of chemotherapeutic agents, the ablation of BRCA1 expression through Hsp90 inhibitors may restore sensitivity to anti-tumor agents, thus representing a possible cancer therapeutic strategy [124,144].